Bailong Chuangyuan released its 2026 interim report, with total operating revenue of 759 million yuan, net profit attributable to the parent company of 211 million yuan, and net cash inflow from operating activities of 441 million yuan. The company's latest asset-liability ratio is 26.56%, up 0.93 percentage points from the previous quarter and up 4.26 percentage points from the same period last year. Gross margin is 43.72%, down 1.38 percentage points from the previous quarter, ROE is 10.02%, and diluted earnings per share is 0.50 yuan. Total asset turnover is 0.29 times, down 4.31% year-on-year, and inventory turnover is 1.39 times, down 27.42% year-on-year. The number of shareholders is 11,800, and the top ten shareholders hold 280 million shares, accounting for 66.71% of the total share capital.
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.Company reports net profit of 211 million yuan in interim report, indicating strong financial performance.